What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
In February 2020, researchers reported a cryo-electron microscopy map of the SARS-CoV-2 spike protein in its prefusion shape, resolved to 3.5 angstroms. The structure showed how the virus’s cell-entry machinery is arranged and gave vaccine and antibody researchers a useful starting point—not evidence that a vaccine had already been shown to work.
What the researchers mapped
Daniel Wrapp and colleagues used cryo-electron microscopy (cryo-EM) to determine the structure of the SARS-CoV-2 spike as a trimer: three spike protein units assembled together. Their study, published online in Science on February 19, 2020, reported a resolution of 3.5 angstroms. The RCSB Protein Data Bank record 6VSB identifies the prefusion spike structure and links it to the study.
As an Amazon Associate I earn from qualifying purchases.
“Prefusion” describes the spike before it changes shape during the process of entering a cell. In the predominant state reported by the team, one of the three receptor-binding domains (RBDs) was rotated upward. This exposed, receptor-accessible arrangement helps explain how the spike can engage its human-cell receptor, ACE2.
A 3.5-angstrom structure is a detailed molecular map, not a photograph of a virus or a complete account of every shape the spike can take. The reported conformation captures a structural state that researchers could analyze and use in further experiments.
#1 Best Overall
Why the spike structure mattered for vaccine and antibody research
The spike mediates the virus’s binding to host cells through ACE2, making it a focus for attempts to prevent or disrupt cell entry. Wrapp and colleagues wrote in their study abstract: “The CoV spike (S) glycoprotein is a key target for vaccines, therapeutic antibodies, and diagnostics.”
A structural map can help scientists examine which parts of a viral protein are exposed, study how antibodies bind, and select or engineer antigens for experiments. In a contemporaneous Chemistry World report published February 20, 2020, study leader Jason S. McLellan described the research goal this way: “The spike is what we want to try and target with vaccines, with antibodies and with small molecules, so that we can prevent the virus from entering cells.” The map thus offered a practical research tool at a time when such work was just beginning.
Rank #2
What the study found about ACE2 and antibodies
In the comparison reported by Wrapp and colleagues, the SARS-CoV-2 spike had approximately 10- to 20-fold higher affinity for ACE2 than the SARS-CoV spike. This is a biophysical measurement from that study, not a measure of disease severity, transmission, or vaccine protection.
The team also found that several tested monoclonal antibodies specific to the SARS-CoV RBD did not appreciably bind the SARS-CoV-2 spike. That is evidence of limited cross-reactivity among the antibodies tested—not proof that all antibodies against SARS-CoV fail to recognize SARS-CoV-2.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What the map did not establish
The structure did not show that a vaccine candidate was safe, produced an immune response in people, or prevented infection or disease. Those are questions that require separate laboratory and clinical evidence. A map can guide antigen design and antibody studies, but it cannot by itself establish that an intervention works.
“Hope for vaccine development” was therefore a forward-looking description of the structure’s research value when it was reported in 2020. The result helped researchers investigate a promising target; it was not, on its own, a vaccine or a clinical outcome.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
